Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Lymphoma 29Precursor Cell Lymphoblastic Leukemia-Lymphoma 18Lymphoma, Large B-Cell, Diffuse 18Lymphoma, Non-Hodgkin 17Neuroblastoma 16Leukemia, Myeloid, Acute 14Leukemia 13Hodgkin Disease 13Central Nervous System Neoplasms 13Small Cell Lung Carcinoma 10Sarcoma 9Brain Neoplasms 9Recurrence 8Medulloblastoma 8Leukemia, Lymphocytic, Chronic, B-Cell 8Rhabdoid Tumor 7Multiple Myeloma 7Lymphoma, B-Cell 7Lung Neoplasms 7Burkitt Lymphoma 7Lymphoma, Mantle-Cell 6Lymphoma, Large-Cell, Immunoblastic 6Lymphoma, Follicular 6Lymphoma, B-Cell, Marginal Zone 6Astrocytoma 6Teratoma 5Ovarian Neoplasms 5Neoplasms, Germ Cell and Embryonal 5Neoplasms 5Glioma 5

Interventions

Cisplatin 7Etoposide 5pembrolizumab 4Topotecan 4Pemetrexed 4Gemcitabine 3Carboplatin 3belinostat 2Temozolomide 2RRx-001 2Paclitaxel 2vosaroxin 1vinflunine 1veliparib 1taxane 1sagopilone 1sacituzumab govitecan 1pomalidomide 1lurtotecan 1liposomal doxorubicin 1etoposide phosphate 1enzalutamide 1bemiparin 1belotecan 1apalutamide 1alvocidib 1abiraterone 1Vinorelbine 1Tomography, X-Ray Computed 1Taxes 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Carcinoma, Small Cell × etoposide phosphate × Clear all
NCT00537511 2019-11-19

A Phase I/II Study to Determine the Maximum Tolerated Dose (MTD) and Safety of CC-4047 (Pomalidomide) Administered in Conjunction With Cisplatin and Etoposide

Celgene

Phase 1/2 Terminated
22 enrolled 13 charts

Carcinoma, Small Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡